Vasculitis & polymyalgia rheumatica
A scoping review of vasculitis as an immune-related adverse event from checkpoint inhibitor therapy of cancer: Unraveling the complexities at the intersection of immunology and vascular pathology
Authors' conclusion
Vasculitis as an irAE appears clinically heterogeneous and rare. Among reported cases with adequate documentation, vasculitis is of delayed onset following the initiation of immunotherapy. Outcomes of ICI-vasculitis were generally favorable, responding to glucocorticoids and immunotherapy withdrawal.
Study context
- Population
- Published biopsy-documented cases of vasculitis as an immune-related adverse event (irAE) from ICI therapy of cancer (PUBMED searches, September and November 2022)24 publications
- Participants
- 29 cases
- Outcome
- Clinical features, ICI treatment, timing of onset and outcomes of biopsy-proven ICI-related vasculitis (single-group case series)
Methodological detailsPRISMA-ScR framework, 2022 ACR/EULAR Vasculitis Classification Criteria and 2012 Revised Chapel-Hill Nomenclature
- PRISMA-ScR framework
- 2022 ACR/EULAR Vasculitis Classification Criteria and 2012 Revised Chapel-Hill Nomenclature
Main finding
As reported in the abstract
- Mean time to onset of symptoms from start of ICI (months)
- 7.2 ± 7.8
- Onset >3 months since initial immunotherapy
- 55.2 %
- Met ACR/EULAR criteria (cases)
- 8
- Small-vessel vasculitis by Chapel-Hill Nomenclature
- 31.0 %; n = 9
- ANCA positive (cases)
- 4
- Treated with GC
- 96 %
- Immunotherapy discontinued
- 44.8 %; n = 13
- Clinical improvement of irAE
- 86.2 % (n = 25)
- Cancer progressed
- 20.7 % (n = 6)
- Cancer stable
- 34.5 % (n = 10)
- All-cause deaths (patients)
- 6
Original publication
A scoping review of vasculitis as an immune-related adverse event from checkpoint inhibitor therapy of cancer: Unraveling the complexities at the intersection of immunology and vascular pathology. Semin Arthritis Rheum. Published 27 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →